Trade press release
July 24, 2025

Covering an area of more than 40,000 square meters, the new competence and production center will primarily be used for the construction of freeze-drying systems. (Photo: GEA)
Covering an area of more than 40,000 square meters, the new competence and production center will primarily be used for the construction of freeze drying systems, which are used worldwide for the manufacture of injectable drugs such as vaccines. The complete relocation of the production, storage, and laboratory areas as well as the administrative functions will take place in the fourth quarter of 2025.
The “Factory of the Future” in Elsdorf stands for future-proof production processes, consistent digitalization, and sustainable construction: The photovoltaic system supplies environmentally friendly electricity, waste heat is recycled, and green roof areas promote a pleasant working environment and a focus on biodiversity. An intelligent warehouse management system and digital workflows ensure increased efficiency and transparency in operations.
The partial approval gives the GEA team access to the first assembly areas while construction work continues elsewhere. This means that the assembly of complex systems can begin at an early stage, avoiding time-consuming relocation of these large components at a later date. The gradual commissioning process guarantees that the project will be completed on time and within budget.

Construction of GEA's new pharmaceutical technology center in Elsdorf (North Rhine-Westphalia) is on schedule. The relocation of the previous operations in Hürth to Elsdorf has now begun. (Photo: GEA)
GEA is one of the world’s largest suppliers of systems and components to the food, beverage and pharmaceutical industries.
The international technology group, founded in 1881, focuses on machinery and plants, as well as advanced process technology, components and comprehensive services. For instance, every second pharma separator for essential healthcare products such as vaccines or novel biopharmaceuticals is produced by GEA. In food, every fourth package of pasta or every third chicken nugget are processed with GEA technology.
With more than 18,000 employees, the group generated sales of about EUR 5.5 billion in more than 150 countries in the 2025 fiscal year. GEA plants, processes, components and services enhance the efficiency and sustainability of customers’ production. They contribute significantly to the reduction of CO2 emissions, plastic usage and food waste. In doing so, GEA makes a key contribution toward a sustainable future, in line with the company’s purpose: ”Engineering for a better world.”
GEA is listed on the German MDAX, the European STOXX® Europe 600 Index and is also a constituent of the leading sustainability indices DAX 50 ESG, MSCI Global Sustainability and Dow Jones Best-in-Class World.